A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study)

Category Primary study
JournalJournal of Clinical Oncology
Year 2023
This article has no abstract
Epistemonikos ID: f6c30fe50ee8cdc5cd3dcc00dec9dda96846408e
First added on: Feb 15, 2025